Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clearmind Medicine Inc.'s SEC filings document foreign private issuer reports for a clinical-stage biotech developing non-hallucinogenic, neuroplastogen-derived psychedelic therapeutics. Form 6-K reports furnish press releases on CMND-100, MEAI-based Alcohol Use Disorder clinical development, European patent activity for PTSD compounds, and communications tied to FDA regulatory pathways.
The filings also record capital-structure matters, including securities purchase agreements, convertible promissory notes, conversions into common shares and amendments to financing capacity. Governance disclosures cover board composition, committee assignments and Nasdaq independence determinations, while incorporated registration statements on Form F-3 and Form S-8 connect current reports to the company's securities registration record.
Clearmind Medicine Inc. has entered a development agreement with Polyrizon Ltd. to create an intranasal formulation of its proprietary, non-hallucinogenic neuroplastogen MEAI. The goal is to enhance drug delivery and support ongoing and future clinical programs targeting addiction-related and other central nervous system disorders.
The collaboration combines Clearmind’s neuroplastogen expertise with Polyrizon’s intranasal hydrogel technology to potentially improve bioavailability, therapeutic effect and patient experience. Polyrizon is a related party under Canadian securities rules, and Clearmind is relying on available exemptions from formal valuation and minority shareholder approval for this related party transaction.
Clearmind Medicine Inc. is drawing additional funding under previously agreed convertible note financing. The company will issue and sell convertible promissory notes with an aggregate principal amount of $2,500,000, for a cash purchase price equal to 90% of principal, or $2,250,000.
The first tranche closed on February 4, 2026 with $600,000 principal for $540,000 in cash. A second tranche of $1,900,000 principal for $1,710,000 in cash will close after Clearmind files a registration statement covering resale of the common shares issuable upon conversion of the notes.
Clearmind Medicine reports that its proprietary compound MEAI (5-MeO-AI), a next-generation, non-hallucinogenic neuroplastogen, has been specifically named in new bipartisan U.S. legislation, the Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091).
The bill would direct the U.S. Department of Veterans Affairs to create investigational research and extended access treatment programs using emerging therapies for unmet medical needs in veterans. Covered therapies include psilocybin, MDMA, MEAI, 5-MeO-DMT, ibogaine, ketamine and others designated by the VA Secretary.
This is the first time MEAI has been referenced in U.S. federal legislation. Clearmind highlights potential applications for conditions such as Alcohol Use Disorder and post-traumatic stress disorder, emphasizing growing policy recognition of innovative, evidence-based psychedelic and neuroplastogen approaches.
Clearmind Medicine Inc. is updating its registration to cover the resale of up to 331,949 common shares issuable upon exercise of January 2024 PIPE warrants. These shares are held by institutional selling shareholders from a January 2024 private placement and prior related financings, and represent a significant portion of the company’s 1,499,838 common shares outstanding as of January 26, 2026.
The company will not receive proceeds from any resale of these shares, but could receive up to approximately $1.3 million if all related warrants are exercised for cash at their current exercise price. A risk factor highlights that resale of these shares, equal to about 22.13% of outstanding shares as of January 26, 2026, could pressure the market price, and notes additional geopolitical risks tied to Clearmind’s operations and personnel presence in Israel.
Clearmind Medicine Inc. filed a post-effective amendment that updates prior registration statements covering the resale of up to 331,949 common shares issuable upon exercise of January 2024 PIPE warrants. These shares are being registered for selling shareholders from a January 2024 private placement and may be sold from time to time on Nasdaq or in negotiated deals. Clearmind will not receive proceeds from any resale of these shares, but could receive up to approximately $1.3 million if the PIPE warrants are fully exercised for cash. As of January 26, 2026, Clearmind had 1,499,838 common shares outstanding, and full exercise of the registered PIPE warrants would increase this to 1,831,787 shares. The filing notes that the 331,949 warrant shares equal about 22.13% of common shares outstanding before this offering, highlighting potential resale overhang for existing shareholders.
Clearmind Medicine Inc. is updating a prior registration and converting it to a Form F-3 to allow the resale of up to 296,130 common shares by existing holders. These shares include 294,969 shares tied to convertible promissory notes and 1,161 shares granted as equity awards. Clearmind has already issued promissory notes with an aggregate principal of $2.5 million, all of which, plus accrued interest, have been converted into 129,287 common shares as of January 26, 2026. The notes convert at the lower of a fixed price of $40.40 or 88% of recent VWAP, but not below a floor of $8.00. Clearmind will not sell any shares in this resale and will not receive proceeds from selling shareholders, though it may receive up to an additional $6.75 million in gross proceeds if it elects to issue more notes under the purchase agreements. Shares outstanding were 1,499,838 as of January 26, 2026, and would be 1,795,968 if all registered note shares are issued.
Clearmind Medicine Inc., a clinical-stage pharmaceutical company focused on psychedelic-based therapies, files its annual Form 20-F reporting continued operating losses and substantial going concern uncertainty. The company recorded operating losses of $5,667,177, $5,744,925 and $6,303,434 for the years ended October 31, 2025, 2024 and 2023, with net losses of $3,856,983, $5,254,678 and $8,620,837, and an accumulated deficit of $27,879,724 as of October 31, 2025.
The auditors include an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern, noting negative operating cash flows of $4,734,498 and reliance on future equity or debt financing. Clearmind reports cash and cash equivalents of $3,923,058 as of October 31, 2025 and remains pre-revenue with no approved products, advancing lead candidate MEAI through early-stage clinical development for alcohol use disorder and other indications under significant regulatory, clinical, funding and commercialization risks.